切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2010, Vol. 04 ›› Issue (02) : 132 -134. doi: 10.3877/cma.j.issn.1674-0793.2010.02.012

所属专题: 文献

论著

谷氨酰胺对胃癌术后化疗患者肠屏障功能的影响
赵晓雷1,(), 何效东1, 崔泉1, 邓志云1, 杨毅1   
  1. 1. 518029 深圳,武警广东边防总队医院外一科
  • 收稿日期:2009-10-16 出版日期:2010-04-01
  • 通信作者: 赵晓雷

Effects of glutamine on intestinal barrier function in patients undergoing postoperative chemotherapy for gastric cancer

Xiao-lei ZHAO1,(), Xiao-dong HE1, Quan CUI1, Zhi-yun DENG1, Yi YANG1   

  1. 1. General Hospital of Guangdong Police Frontier Defense, Shenzhen 518029, China
  • Received:2009-10-16 Published:2010-04-01
  • Corresponding author: Xiao-lei ZHAO
  • About author:
    Corresponding author: ZHAO Xiao-lei, Email:
引用本文:

赵晓雷, 何效东, 崔泉, 邓志云, 杨毅. 谷氨酰胺对胃癌术后化疗患者肠屏障功能的影响[J/OL]. 中华普通外科学文献(电子版), 2010, 04(02): 132-134.

Xiao-lei ZHAO, Xiao-dong HE, Quan CUI, Zhi-yun DENG, Yi YANG. Effects of glutamine on intestinal barrier function in patients undergoing postoperative chemotherapy for gastric cancer[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2010, 04(02): 132-134.

目的

观察谷氨酰胺对胃癌术后化疗患者肠屏障功能的影响。

方法

40例胃癌术后第4次化疗患者随机分为对照组和试验组,化疗方案为氟尿嘧啶(5-FU)、四氢叶酸(CF)加奥沙利铂(FOLFOX方案)。试验组化疗同时口服谷氨酰胺(30 g/d),对照组化疗时未口服谷氨酰胺,检测两组患者化疗前后血浆谷氨酰胺浓度、二胺氧化酶(DAO)、D-乳酸水平及粪便中肠道菌群情况。

结果

化疗后对照组血浆谷氨酰胺浓度较化疗前明显降低(P<0.05),试验组增加并明显高于对照组(P<0.01);化疗后两组血浆DAO水平较化疗前均明显升高(P<0.01),对照组较试验组升高更为明显(P<0.05);对照组D-乳酸水平化疗后升高(P<0.05),与试验组比较差异有统计学意义;试验组患者各肠道菌群总数化疗前后无明显变化,肠道菌群接近正常比例;对照组双歧杆菌、乳杆菌较化疗前明显下降(P<0.01),大肠埃希菌、肠球菌明显升高(P<0.01)。

结论

口服谷氨酰胺可提高胃癌术后化疗患者血浆谷氨酰胺浓度,有减轻损伤、调节肠道菌群微生态平衡、保护肠屏障功能的作用。

Objective

To study the effects of glutamine on intestinal barrier function in patients undergoing postoperative chemotherapy for gastric cancer.

Methods

Forty patients with gastric cancer after operation who accepted the fourth chemotherapy were randomly divided into Gln group and control group. The former received oral administration of glutamine (30 g/d) for 7 days. All patients received CF+5-FU+Oxalipatin chemotherapy, namely FOLFOX formula, for 5 days. Serum concentration of glutamine, DAO and D-lactate were measured before and l day after chemotherapy. Changes of microflora in stool were also studied by bacterial culture.

Results

After chemotherapy, the serum concentration of glutamine was significantly decreased in the control group(P<0.05)and increased in the Gln group(P<0.01), and there was significant difference between the two groups(P<0.01). The levels of DAO in the two groups after chemotherapy were significantly higher than those before treatment(P<0.01), while they were significantly higher in the control group than those in the Gln group(P<0.05). The levels of D-lactate in the control group were significantly higher than those in the Gln group(P<0.05). Bacterial culture revealed that the amount of bifidobaterium and lactobacilli were markedly increased while escherichia coli and enterococcus faecalis decreased in the control group.

Conclusion

Oral administration of glutamine can increase serum concentration of glutamine in chemotherapy patients with gastric cancer and shows the protective effects on gut barrier function by alleviating the damage of intestinal mucosa and microecologic disturbance.

表1 40例胃癌患者化疗前后血浆谷氨酰胺浓度、DAO及D-乳酸活性变化(±s
表2 40例胃癌患者化疗前后肠道菌群变化(ln/g,±s
1
Kwon C, Seung S, Suk J, et al. The effect of oral glutamine on 5-fluoro uracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr, 2007, 10(5):639-659.
2
李仲南,汪昱,秦环龙. 化疗药物对肠屏障功能的损伤机制及防治进展. 山东医药,2008,48(26):113-115.
3
邓宇,许瑞云,刘波等. Gln与rhGh对肝硬化病人肠黏膜屏障的影响. 中国现代医学杂志, 2006, 16(15):2336-2338.
4
果磊,黄崇本. 谷氨酰胺在肠道的代谢及其作用. 中国药房, 2005, 16(4):305-307.
5
XI P, HONG Y, ZHONG YY, et al. Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients. Burns, 2004, 30(1):135-139.
6
Erick V, Angelam M, Gil H. Impact of oral L-glutamine on glutathione, glutamine, and glutamate blood levels in volunteers. Nutrition, 2002, 18(2):367-370.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[6] 薛庆, 施赛叶, 徐雅文, 盛夏, 张芹芹. 追踪方法学联合失效模式与效应分析在膀胱灌注化疗患者中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 553-559.
[7] 刘先勇, 秦东梅, 张若梅, 李俊娇, 孟春芹, 邬明歆, 王玉红, 赵新鲜, 徐瑞联, 洪文文, 马玲, 仇玮, 周宇. Her2/Hes1在肠型胃癌Correa级联反应3个病理阶段中的表达及意义[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 321-327.
[8] 张昊, 潘卫东. 胰腺癌新辅助化疗后可切除性评估现状及进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 629-633.
[9] 王军华, 王锐炫. 胰腺癌新辅助化疗现状和治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 640-643.
[10] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[11] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[12] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[13] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[14] 张颖, 赵鑫, 陈佳梅, 李雁. 术前化疗对CRS+HIPEC 治疗腹膜假黏液瘤预后影响的meta 分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 826-835.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要